SGLT2 Inhibitors
SGLT2 inhibitors work in the kidney, blocking the transporter that reabsorbs glucose back into the blood — so excess sugar leaves in the urine. They began as diabetes drugs, but large trials found they also protect the heart and kidneys, cutting hospitalisation for heart failure even in people without diabetes. That has made them a cornerstone of cardiology and nephrology as much as of diabetes care.
3 SGLT2 Inhibitors in this directory
Compare SGLT2 Inhibitors side by side
Browse other drug classes
How this page is built
The facts on this page are pulled directly from official U.S. FDA datasets — they are not written from memory. Each field below names the dataset it came from, so you can check it yourself.
- FDA Drug Label (openFDA) ↗ Indications, mechanism of action and pharmacologic class
- Drugs@FDA ↗ First FDA approval date and the company holding the application
- FDA Drug Shortage Database ↗ Current US supply / shortage status
Plain-English summaries and drug-class explainers are written and reviewed by Sreepriya Prasannan (MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany). Data is retrieved automatically from the sources above and cross-checked with AI-assisted verification (Anthropic's Claude) — brand and generic names are matched against the exact FDA product record so that a combination product or a different formulation cannot be mistaken for the drug on this page. An editor reviews the result before publication. We describe this in full in our editorial standards and corrections policy. The FDA data on this page was last retrieved on 12 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.